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IT has been shownlong ago that shielding the bone marrow (Kaplan and Brown,
1951) or spleen (Lorenz et al., 1953) of mice during exposure to whole-body
X-irradiation, or injection of syngeneic bone marrow cells after whole-body
irradiation (Kaplan et al., 1953), reduces the incidence of thymic lymphomas
resulting from the irradiation. How the effect is brought about has never been
satisfactorily explained. There is presumably some essential factor in the normal
hematopoietic system which irradiation is able to depress. Whether this
inhibitory process affects a specific stage in radiation leukaemogenesis, or whether
it is concerned with the leukaemogenic process as such, irrespective of the nature
of the leukaemogenic agent, has not so far been fully established. Indirect
evidence would suggest, however, that the former (i.e. a specific anti-radiation
effect) is the more likely explanation.
Itisknown, forinstance, thatbonemarrow cells ofC3H mice, though acceptable
to tolerant AKR mice, fail to inhibit the spontaneous development of thymic
lymphomas in the latter strain (Miller, 1960). In the case ofleukaemogenesis by
the combined action of X-irradiation and estrogen injection, the estrogen almost
nullified the protective effect of thigh shielding (Toch et al., 1956). In previous
experiments in this laboratory (Berenblum et al., 1966), it has also been shown that
normal syngeneic bone marrow cells fail to inhibit urethane Jeukaemogenesis in
newborn C57BL mice. The results with cell-free extracts of sheep spleen (a
protein component-RLP-recently characterized as 19S alpha-2 globulin
(Berenblum et al., 1968), capable of inhibiting radiation leukaemogenesis in
C57BL mice, but not of the spontaneous disease in AKR mice (Berenblum et al.,
1967), also supports the view that the inhibition is strictly anti-radiation in its
mode of action.
A critical factor in the inhibition of radiation leukaemogenesis by syngeneic
bone marrow cells is the time ofinjection ofthe cells in relation to the irradiation.
Foreffective inhibition, the cell suspension mustbeinjectedwithin afewhours after
the last irradiation (Kaplan et al., 1955). In the urethane experiment quoted
above (Berenblum et al., 1966), the bone marrow cell suspension was injected
2-4 days after the urethane injection, in order to avoid the possibility ofthe bone
marrow cells being damaged by the urethane in vivo. The interpretation of the
results (failure of the bone marrow cells to interfere with urethane leukaemo-
genesis), might therefore seem less convincing than would be desired.
The present series of experiments, using 3-methylcholanthrene (MC) as the
chemical leukaemogenic agent, and dba/2 mice as test animals, were designed to
overcome these limitations.SYNGENEIC BONE MARROW CELLS
MATERIALS AND METHODS
Animal8
The dba/2 mice used in these experiments were obtained from the Jackson
Laboratory, Bar Harbor, Maine. They were kept for a week or more before use,
to acclimatize them to the conditions of the laboratory, and so that they should
reach therequired age fortherespective experiments. The animals were housed in
an air-conditioned room at 21-24° C., fed Purina Laboratory Chow, supplemented
occasionally with barley and sunflower seeds, and provided with tap water ad
libitum.
X-rays
The X-irradiation was performed with a General Electric Maximar 250-III
machine. The physical factors were: 250 kv., 15 mA., with 1 mm. Al and 0 5 mm.
Cu filters: dose rate 61 R/minute for the 200 R and 800 R exposures, and 37 R/
minute for the 150 R exposure.
In Expt. I, male and female mice, 6 weeks old at the start of the experiment,
received 12 applications of 3-MC to the skin, under the following conditions:
a single drop of 0.25 per cent MC in acetone (containing approximately 1 ,tg. MC)
was applied 3 times aweek to different areas ofskin inrotation, therebyminimizing
the local development of tumours. Previous removal of hair was performed by
means of an electric clipper. The mice were then divided into 2 groups: Group 1
received no further treatment; Group 2 was given, in addition, 3 intravenous
injections of bone marrow cells 2-3 hours after the third, sixth and twelfth MC
application. The bone marrow cells were in the form of a suspension containing
15 x 106 cells per injection, prepared according to the procedure described
previously (Berenblum et al., 1966). A third group of mice, of both sexes and of
the same age, was kept without any treatment, to provide information about the
spontaneous incidence of leukaemia in the strain under the conditions of this
laboratory.
Two additional experiments were set up to test the effectiveness of the bone
marrow suspensions derived from MO-treated mice:
To test the ability of the cell suspension to repair radiation damage to the
thymus (Expt. II), 6-week-old male mice were given 2 exposures of 200 R each
at 7-day intervals, and then divided as follows: One group received 15 x 106
syngeneic bone marrow cells from mice pretreated with 12 applications of MC.
The bone marrow cells were taken from the donors 2-3 hours after the last MC
treatment. A second group was injected with an equivalent number of bone
marrow cells from normal untreated mice. In both groups the bone marrow cells
were injected 2-3 hours after the second irradiation. In the third group, no
bone marrowinjection was given. Afourthgroupwaskeptwithoutanytreatment.
The animals were killed 21 days after the last irradiation, and thymic weights
were determined.
To test for the ability of bone marrow from pretreated animals to protect
lethally-irradiated mice (Expt. III), male mice, 3-4 months old, were given a
single lethal dose of 800 R of total-body X-irradiation. The irradiated mice
were divided into 3 groups, and treated similarly to those in the previous experi-
ment. The first group received bone marrow from MC-treated mice; the second
group received bone marrow from untreated mice; and the third group served
as irradiated, uninjected control mice.
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The effectiveness of bone marrow with respect to survival was determined
by the number of survivors 60 days after irradiation.
In order to compare MC-induced leukaemogenesis with radiation-induced
leukaemogenesis in dba/2 mice, the following experiment (IV) was also included:
Two groups of mice of both sexes were submitted to 4 weekly exposures of
150 R each of total-body X-irradiation (totalling 600 R). Approximately 3-4
hours after the last irradiation, the mice of Group 1 received one intravenous
injection of a normal bone marrow cell suspension, containing 15 x 106 cells per
injection. The mice of Group 2 served as uninjected controls.
RESULTS
The results of Expt. I are summarized in Table I. Twelve applications of
TABLE I.-Incidence ofLymphatic Lymphomas in dba/2 Mice Given MC
andSyngeneic Bone Marrow
No. of Incidence of Average latent
mice No. of lymphomas/ lymphomas period
Group Treatment Sex used effective total* (%) (weeks)
1 MC * . 22 13/22 . 59 . 25 3
<3 . 35 6/32 19 . 42 6
Total 57 19/54 35 30 8
2 .MC + bone. S 22 . 11/21 52 . 30 9
marrow . 31 5/27 . 19 . 27- 2
Total 53 . 16/48 33 29 7
3 .Untreated. S . 5 . 0/5 0
d . 18 . 0/18 . 0 . -
Total 23 . 0/23 0
* Effective total = number of survivors at time of appearance of first leukaemia.
MC alone yielded a 35 per cent incidence ofleukaemia at a mean age of30.8 weeks;
while such treatment together with 3 injections ofnormal syngeneic bone marrow
yielded a similar incidence ofleukaemia (33 per cent) with a mean latent period of
29.7 weeks. A remarkable sex difference was observed in both groups, the females
developing 3 times more leukaemia than the males. Twenty-three untreated
controls ofboth sexes remained free from leukaemia during a period ofobservation
of 55 weeks.
In the autopsy findings, there was swelling of the liver and spleen, and great
enlargement ofallthelymph nodes. The enlargement ofthethymus wasrelatively
slight. Histologically, neoplastic tissue was of stem cell or lymphoblastic type.
In Table II are presented the results of Expt. II, in which equal numbers of
bone marrow cells from normal and MC-treated donors were tested for their
ability to promote thymic regeneration in sublethally irradiated mice. The mean
thymic weight ofthe untreated dba/2 mice was 30-7 + 4-3 mg. Twenty-one days
after 2 exposures to irradiation, the mean thymic weight dropped to 16.6 ± 2-9 mg.
Bone marrow from animals treated with MC, when injected to irradiated mice, led
to regeneration of the damaged thymus, as manifested by increasing thymus
weight to 37*3 ± 3-4 mg., somewhat similar to the results with bone marrow
from normal donors-40-2 ± 4.8 mg. The mean thymic weight of irradiated
mice without added treatment, and of those which received bone marrow from
MC-treated animals, differed significantly (P < 0-001).
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TABLE II.-Effect ofBone Marrow Pretreated with MC on Thymic
Recovery in Sublethally Irradiated Mice
Group Treatment
1 . 200 R x 2 followed by bone
marrow from MC pretreated mice
2 . 2000 R x 2 followed by normal
bone marrow
3 . 200 R x 2
4 . None
No. of
recipients
17
16
15
15
Mean thymic weight
± standard deviation
(mg)
37-3±3-4
40*2±4 8
16*6±2-9
30* 7±4 3
* t = Significance of the difference between the mean thymic weight of experimental group 1 and
control group 3 as evaluated by the t test.
TABLE III.-Effect of Bone Marrow Pretreated with MC on the Survival of
Lethally Irradiated Mice
Treatment
800 R followed by bone marrow
from MC pretreated mice
800 R followed by normal bone
marrow
800 R
60-day sur'7ival
rate
Per cent
survival
15/16 . 94
13/15 . 87
0/16
In Expt. III, it was found that MC did not diminish the ability ofbone marrow
to protect lethally-irradiated animals. Sixty-day survival was 94 per cent in the
mice irradiated with 800 R and injected with bone marrow from MC-treated mice,
and 87 per cent in those irradiated and injected with normal bone marrow. All
the irradiated control animals died at day 13.
TABLE IV.-Incidence ofLymphatic Lymphomas in dba/2 Mice Irradiated
and Injected with Syngeneic Bone Marrow
Group Treatment Sex
1 . 150 R x 4 *
-
2 150R x 4
followed by
normal bone
marrow
No. of
mice
used
54
35
Total . 89
y . 11
d . 30
Total . 41
No. of lymphomas/
effective total*
26/51
5/32
31/83
3/11
0/27
3/38
Incidence of
lymphomas
(%)
50
17
37
27
Average latent
period
(weeks)
43X1
41.4
42-7
50 3
0
8 . 50.3
* Effective total = number of survivors at time of appearance of first leukaemia.
The results of Expt. IV showed that dba/2 mice irradiated with 150 R x 4
developed an incidence of 37 per cent lymphomas at a mean latent period of 42-7
weeks, and showed the same significant sex difference as was found in the previous
experiment: 50 per cent lymphomas in females and 17 per cent in males. Normal
bone marrow inhibited lymphoma induction, decreasing the total incidence to
. <0.001
0
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8 per cent after a latent period of 50 3 weeks. An incidence of 27 per cent
lymphomas was still found in females, compared with 0 per cent in males.
DISCUSSION
From the experiments presented here, it may be concluded that synegenic
bone marrow cells, injected into MC-treated dba/2 mice, fail to inhibit leukaemo-
genesis (lymphoma induction), though they do inhibit radiation leukaemogenesis,
as in the case ofC57BL mice.
Previous studies (Kaplan and Brown, 1957) have shown that whole-body
X-irradiation can destroy hematopoietic cells, and the suggestion has been put
forward that this might play an important role in leukaemogenesis. On the other
hand, the present results do not indicate that chemical leukaemogenesis (with MC)
causes significant damage to the hematopoietic system under the conditions used,
since bone marrow suspensions from such treated animals were found to be as
effective as normal bone marrow suspensions in (a) repairing acute radiation
damage in the thymus, and (b) preventing the lethal action of higher doses of
whole-body irradiation.
Earlier evidence (Toch et al., 1956; Miller, 1960; Berenblum et al., 1966),
referred to intheIntroduction, alreadyindicated thatinhibition ofleukaemogenesis
by bone marrow cells is probably specific for radiation leukaemogenesis, and not
operative in spontaneous leukaemia development or in chemical leukaemogenesis.
The present results fully support this conclusion. This does not necessarily mean
that the mechanisms of leukaemogenesis in spontaneous, radiation-induced and
chemically-induced leukaemia, are different, but merely indicates that radiation
leukaemogenesis is a more elaborate process, and that one of the complicating
factors-some specific damage to the hematopoietic system-can be counteracted
by injection of normal syngenic bone marrow cells. The effect, in short, is on
recovery from radiation damage, as distinct from on the sequence of biological
changes in the development ofleukaemia. It is interesting to note in this connec-
tion that injection of bone marrow cells, which is effective in protecting against
lethal doses of radiation, does not prevent the mortality resulting from lethal
doses of a chemical leukaemogen (Congdon et al., 1964).
Following earlier conflicting evidence (see Miller, 1961), recent results of
Haran-Ghera and Peled (1967) support the view that the protective action of
hematopoietic cells is associated with a restoration of the depressed immune
response resulting from the irradiation. Experiments are now in progress here to
test whether chemical carcinogens, employed for leukaemogenesis, also affect the
immunological potency of bone marrow cells, and if so, whether this could also
play a critical role in leukaemogenesis.
Female mice are generally more susceptible than male mice to spontaneous
lymphoma development (McEndy et al., 1944) or to lymphoma induction by
X-irradiation (Kaplan andBrown, 1952), thoughinthe caseoflymphomainduction
by MC skin painting in dba/2 mice, little or no sex difference in incidence was
reported by previous workers (Andervont and Dunn, 1953; Kirschbaum et al.,
1955). Our results with MC skin painting in dba/2 mice did show a striking sex
difference, the incidence in females being about 3 times that in males. Estrogens
are known to enhance the leukaemogenic action of MC in dba/2 mice, which are,
in fact, susceptible to this chemical alone (Kirschbaum et al., 1953). Since
586SYNGENEIC BONE MARROW CELLS 587
female mice have a higher endogenous estrogen than male mice, a lower dose of
MC might be effective for leukaemogenesis in females than in males, while this
difference might be masked when excessive doses of MC are given. This could
explain the difference in sex ratio between our results with MC and those reported
by others (Kirschbaum and Mixer, 1947; Kirschbaum et al., 1955).
SUMMARY
Injections of a suspension of syngeneic bone marrow cells to methylchol-
anthrene-treated adult dba/2 mice failed to inhibit the induction of leukaemia
(lymphoma), in contrast to its inhibiting effect on radiation-induced leukaemia
in the same strain. That the MC did not itself destroy the injected bone marrow
cells was checked by independent tests. The results suggest a specific anti-
radiation effect of bone marrow cells rather than a general antileukaemic
influence.
The incidence oflymphomas following 12 applications ofMC was about 3 times
higher in females than in males. A possible interpretation of these findings is
discussed.
This investigation was supported by U.S. Public Health Service Research
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